Functional Glycomics in HIV Vaccine Design (R01) | Apply Online

Opportunity Summary:

The NIH grant opportunity "Functional Glycomics in HIV Vaccine Design (R01)" (Funding Opportunity Number PA-12-105) is a discretionary research grant program aimed at advancing HIV vaccine development by focusing on glycans, the sugar molecules attached to proteins and lipids that heavily influence how the immune system sees and responds to HIV. The core scientific premise behind the announcement is that glycans are not just decorative features on the HIV-1 envelope (Env) protein; they are central to how the virus transmits, how exposed or hidden key antibody targets are (antigenicity), and how well immune responses are induced and shaped (immunogenicity). Because the Env surface is densely glycosylated, the "glycan shield" can both block immune recognition and, in some cases, create or stabilize targets recognized by broadly neutralizing antibodies. In parallel, glycans are also known to regulate immune signaling and cell-cell interactions, meaning they can affect both innate and adaptive immunity. This FOA is designed to leverage that dual importance by pushing the field to treat glycosylation as an active design variable in vaccine development rather than a passive byproduct of protein production.

The FOA specifically seeks multidisciplinary, investigator-initiated, and collaborative research that addresses two main objectives. First, it encourages projects that examine the structural and conformational features of glycosylation that could open up new strategies for HIV vaccine design. This includes understanding how particular glycan types, positions, and processing states influence the three-dimensional shape and dynamics of Env, how they mask or reveal conserved epitopes, and how they contribute to the formation of antibody binding sites that may depend on both protein and glycan elements. Work in this area typically draws from structural biology, glycomics and glycoproteomics, computational modeling, virology, and protein engineering, with the end goal of translating glycan-focused insights into immunogen designs that better guide the immune system toward protective responses.

Second, the announcement calls for studies that clarify how differences in glycosylation affect the quality of the immune response to HIV. "Differential glycosylation" can arise from viral sequence variation, from changes in how host cells process glycans, or from deliberate manipulation during vaccine antigen manufacturing (for example, expression systems and production conditions that alter glycan composition). NIH is highlighting the need to understand how these glycosylation differences influence the magnitude, specificity, durability, and functional profile of immune responses, including not only neutralizing antibody breadth and potency but also effector functions that depend on Fc-mediated mechanisms and the broader coordination between innate and adaptive immunity. In practical terms, this could include dissecting how glycan patterns steer B cell recognition and maturation pathways that are thought to be necessary for generating broadly neutralizing antibodies, and how glycan-dependent interactions with lectin receptors or other immune modulators shape early immune priming.

From a programmatic standpoint, the opportunity uses the R01 mechanism, meaning it is intended for substantial, hypothesis-driven research projects that can support a focused team and a multi-year research plan. There is no cost sharing or matching requirement. The activity aligns with NIH health research areas under CFDA 93.855 (Allergy and Infectious Diseases Research) and 93.856 (Microbiology and Infectious Diseases Research). The sponsoring agency is the National Institutes of Health, and the full announcement was posted on February 14, 2012, with the original closing date listed as January 7, 2015, though the provided record indicates a current closing date of May 7, 2013 and an archive date of June 7, 2013, reflecting that this particular FOA is now archived rather than open for new submissions.

Eligibility for this FOA is broad and includes a wide range of domestic and non-domestic applicants. Eligible applicants include for-profit organizations (including those other than small businesses), small businesses, nonprofits (including 501(c)(3) organizations and certain nonprofits without 501(c)(3) status), public and private institutions of higher education, and multiple levels of government (state, county, city/township, special district governments), as well as public housing authorities and independent school districts. The eligibility language also explicitly includes many mission-driven and capacity-building institution types such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and faith-based or community-based organizations. Importantly, foreign institutions and other non-U.S. entities are eligible to apply, and foreign components of U.S. organizations are allowed under NIH policy, signaling NIH interest in drawing from global expertise and resources relevant to HIV.

Overall, the grant opportunity is centered on the idea that a truly effective prophylactic HIV vaccine may require design approaches that intentionally incorporate glycan biology. By supporting research that maps how glycosylation shapes Env structure and immune visibility, and by clarifying how glycan differences influence immune response quality and antibody maturation, the FOA aims to generate actionable knowledge for next-generation immunogen engineering. The long-term vision described in the announcement is a safe and effective vaccine that provides durable protection against HIV infection, with glycan-aware vaccine designs helping to elicit and mature broadly neutralizing antibodies as well as other protective effector immune responses.

Source link provided in the notice: http://grants.nih.gov/grants/guide/pa-files/PA-12-105.html

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Health

Next opportunity: Mucosal Environment and HIV Prevention (MEHP) (R01)

Previous opportunity: Notice of Intent to Award Carse Brook Wetland Restoration

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PA 12 105

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PA 12 105) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PA 12 105", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.